SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-18-000554
Filing Date
2018-01-12
Accepted
2018-01-12 06:32:30
Documents
16
Period of Report
2018-01-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K avir20180111_8k.htm 8-K 33555
2 EXHIBIT 99.1 ex_102927.htm EX-99.1 32521
3 EXHIBIT 99.2 ex_102928.htm EX-99.2 8863
4 a12.jpg GRAPHIC 121007
5 a11.jpg GRAPHIC 144154
6 a10.jpg GRAPHIC 151060
7 a09.jpg GRAPHIC 171526
8 a08.jpg GRAPHIC 173198
9 a07.jpg GRAPHIC 123233
10 a06.jpg GRAPHIC 139310
11 a05.jpg GRAPHIC 156807
12 a04.jpg GRAPHIC 176685
13 a03.jpg GRAPHIC 202070
14 a02.jpg GRAPHIC 271416
15 a01.jpg GRAPHIC 73053
16 logo.jpg GRAPHIC 9036
  Complete submission text file 0001437749-18-000554.txt   2711519
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35285 | Film No.: 18524660
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1